fda approves semaglutide weight-loss drug Wegovy to reduce heart-disease risks FDA Approves Oral Semaglutide for

As these weight-loss medications have gained popularity potentially helping obesity rates drop for the first time in a decade theyve also seemed to reduce patients alcohol use, too

However, no peer-reviewed trials have confirmed that adding glutathione amplifies GLP-1 weight loss outcomes in humans

Blum-Degena, D

Providing adolescents with obesity another option Wegovy is the only once-weekly injectable GLP-1 RA indicated to reduce excess body weight and maintain weight reduction long term in combination with diet and exercise in adolescents with obesity aged 12 years and older 3 The safety and effectiveness of Wegovy injection have not been established in pediatric patients to reduce the risk of major adverse CV events or to reduce excess body weight and maintain weight reduction long term in those less than 12 years of age

On the other hand, FDA-approved medications like Wegovy and Zepbound offer a proven path to weight loss with significantly lower risks